Patients With NSCLC, T790M-positivity in Plasma Face Similar Outcomes With Osimertinib

Share this content:
Patients with NSCLC positive for T790M in plasma may have osimertinib-related outcomes equivalent to patients positive by a tissue-based assay.
Patients with NSCLC positive for T790M in plasma may have osimertinib-related outcomes equivalent to patients positive by a tissue-based assay.

Patients with advanced non-small cell lung cancer (NSCLC) positive for T790M in plasma may have osimertinib-related outcomes equivalent to patients positive by a tissue-based assay, according to a study published in the Journal of Clinical Oncology.1 These findings suggest that some patients could avoid a tumor biopsy for T790M genotyping when validated plasma T790M assays become available.

Researchers collected plasma from patients who had acquired EGFR-TKI resistance and evidence of a common EGFR-sensitizing mutation in a first human study of osimertinib.

BEAMing (a digital polymerase chain reaction test) was used to perform genotyping of cell-free plasma DNA, which was assessed for plasma genotyping accuracy by using tumor genotyping from a central laboratory as reference. Objective response rate and progression-free survival were analyzed in all patients who were T790M-positive or T790M-negative.

The researchers found a 70% sensitivity of plasma genotyping for detection of T790M. Among 58 patients with T790M-negative tumors, T790M was found to be detected in the plasma of 18.

Objective response rate and median progression-free survival were found to be similar in patients with T790M-positive plasma or T790M-positive tumor results.

RELATED: NDA Submission Initiated for Brigatinib in ALK+ Non-small Cell Lung Cancer

While patients with T790M-negative plasma were found to have overall favorable outcomes, tumor genotyping distinguished a subset of patients positive for T790M who had better outcomes, along with a subset of patients negative for T790M with poor outcomes.

Reference

  1. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. [published online ahead of print June 27, 2016.] J Clin Oncol. doi: 10.1200/JCO.2016.66.7162.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs